3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap

Every cloud has a silver lining. Sometimes, they have two. That's the case with many stocks in the current market downturn. Dividend yields are higher. Valuations are lower. And those are two big pluses for income investors.

Some stocks have especially attractive dividend yields and valuations. Here are three dirt cheap, ultra-high-yield dividend stocks to buy right now.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

1. Ares Capital

Ares Capital's (NASDAQ: ARCC) forward dividend yield is a sky-high 9.42%. The stock trades at a low forward earnings multiple of 9.6. You could make a strong argument that Ares Capital is an income investor's dream stock.

To be sure, Ares Capital isn't immune to all the volatility affecting the stock market. Shares of the business development company (BDC) are still down by a double-digit percentage below their peak from earlier this year, despite a nice rebound.

Ares Capital could experience some pain if the economy falters and the middle-market businesses it serves require less access to capital. On the other hand, it's possible that more of those businesses could turn to BDCs, such as Ares, instead of banks during an economic downturn.

Regardless of what happens over the near term, Ares Capital should be a solid winner over the long term. The company has delivered roughly 70% greater total returns than the S&P 500 since its initial public offering in 2004. I expect that outperformance will continue in the future.

2. Enterprise Products Partners

As a limited partnership (LP), Enterprise Products Partners (NYSE: EPD) pays distributions to unitholders rather than dividends to shareholders. Whatever you call it, though, it's juicy: Enterprise's forward distribution yield tops 6.8%. The company has also increased its distribution for an impressive 26 consecutive years.

Enterprise Products Partners trades at only 10.3 times forward earnings, well below the average forward earnings multiple of 13.4 for the S&P 500 energy sector. However, I think Enterprise's valuation is even better than it appears at first glance, considering the reliability of its cash flow.

Unlike oil and gas producers, Enterprise Products Partners' revenue doesn't fluctuate in tandem with commodity prices. As long as oil, natural gas, natural gas liquids, or other hydrocarbons are flowing through the company's 50,000+ miles of pipeline, Enterprise doesn't care what the price of those liquids is.

Enterprise Products Partners' business is largely recession-resistant. I also like that most of its revenue is protected from inflation, with around 90% of the company's long-term contracts containing inflation-based escalation provisions.

3. Pfizer

Pfizer's (NYSE: PFE) forward dividend yield of 7.72% is near its highest level since the Great Recession. The big pharma stock is cheap, too, with shares trading at 7.5 times forward earnings. The ultra-high yield and the dirt cheap valuation are both byproducts of Pfizer's steep sell-off that began in late 2021 and has continued this year.

Bad news has been a recurring theme for Pfizer. COVID-19 vaccine sales have plunged, the company faces a looming patent cliff for several of its top products, and Pfizer recently threw in the towel on its oral weight-loss candidate, danuglipron, due to safety concerns.

However, Pfizer's outlook isn't as gloomy as it might seem. The company has several newer products with fast-growing sales, notably including migraine therapy Nurtec ODT and cancer drugs Adcetris and Padcev. Pfizer's pipeline features 32 programs in late-stage clinical development.

Pfizer recently announced its 16th consecutive annual dividend increase. The drugmaker should be able to maintain that streak. Wall Street also thinks the stock has plenty of room to run, with the consensus 12-month price target reflecting an upside potential of nearly 35%.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,747!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $622,041!*

Now, it’s worth noting Stock Advisor’s total average return is 792% — a market-crushing outperformance compared to 153% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 14, 2025

Keith Speights has positions in Ares Capital, Enterprise Products Partners, and Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy.